Tags

Type your tag names separated by a space and hit enter

Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
Gastroenterology. 2010 Nov; 139(5):1612-8.G

Abstract

BACKGROUND & AIMS

Hepatitis E virus (HEV) infection can evolve to chronic hepatitis in immunocompromised patients. Pegylated α-interferon can effectively treat chronic HEV infection after liver transplantation but is contraindicated for kidney transplantation. We assessed the antiviral effect of ribavirin monotherapy in patients with chronic HEV infection following kidney transplantation.

METHODS

In a pilot study performed at Toulouse University Hospital, 6 patients that received kidney transplants who were positive for HEV RNA (infected with HEV for 36.5 months; [range, 11-46 months]) were given ribavirin monotherapy for 3 months. Ribavirin was given at 600-800 mg/day in 2 separate doses, based on the patient's ability to clear creatinine.

RESULTS

Median serum concentration of HEV RNA at baseline was 5.77 log copies/mL (range, 4.35-7.35 log copies/mL). Three months after ribavirin therapy commenced, HEV RNA was undetectable in serum samples from all patients. A sustained virologic response was observed in 4 patients; the other 2 patients relapsed at 1 and 2 months after ribavirin therapy ended. At the end of the study, all patients had normal levels of alanine and aspartate aminotransferase. Anemia was the main side effect caused by ribavirin therapy.

CONCLUSIONS

Ribavirin monotherapy inhibits the replication of HEV in vivo and might induce a sustained virological response in patients with chronic HEV infections. Further studies are required to determine the optimal duration of ribavirin therapy.

Authors+Show Affiliations

Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France. kamar.n@chu-toulouse.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

20708006

Citation

Kamar, Nassim, et al. "Ribavirin Therapy Inhibits Viral Replication On Patients With Chronic Hepatitis E Virus Infection." Gastroenterology, vol. 139, no. 5, 2010, pp. 1612-8.
Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology. 2010;139(5):1612-8.
Kamar, N., Rostaing, L., Abravanel, F., Garrouste, C., Lhomme, S., Esposito, L., Basse, G., Cointault, O., Ribes, D., Nogier, M. B., Alric, L., Peron, J. M., & Izopet, J. (2010). Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology, 139(5), 1612-8. https://doi.org/10.1053/j.gastro.2010.08.002
Kamar N, et al. Ribavirin Therapy Inhibits Viral Replication On Patients With Chronic Hepatitis E Virus Infection. Gastroenterology. 2010;139(5):1612-8. PubMed PMID: 20708006.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. AU - Kamar,Nassim, AU - Rostaing,Lionel, AU - Abravanel,Florence, AU - Garrouste,Cyril, AU - Lhomme,Sebastien, AU - Esposito,Laure, AU - Basse,Grégoire, AU - Cointault,Olivier, AU - Ribes,David, AU - Nogier,Marie Béatrice, AU - Alric,Laurent, AU - Peron,Jean Marie, AU - Izopet,Jacques, Y1 - 2010/08/11/ PY - 2010/04/22/received PY - 2010/07/27/revised PY - 2010/08/04/accepted PY - 2010/8/17/entrez PY - 2010/8/17/pubmed PY - 2010/12/14/medline SP - 1612 EP - 8 JF - Gastroenterology JO - Gastroenterology VL - 139 IS - 5 N2 - BACKGROUND & AIMS: Hepatitis E virus (HEV) infection can evolve to chronic hepatitis in immunocompromised patients. Pegylated α-interferon can effectively treat chronic HEV infection after liver transplantation but is contraindicated for kidney transplantation. We assessed the antiviral effect of ribavirin monotherapy in patients with chronic HEV infection following kidney transplantation. METHODS: In a pilot study performed at Toulouse University Hospital, 6 patients that received kidney transplants who were positive for HEV RNA (infected with HEV for 36.5 months; [range, 11-46 months]) were given ribavirin monotherapy for 3 months. Ribavirin was given at 600-800 mg/day in 2 separate doses, based on the patient's ability to clear creatinine. RESULTS: Median serum concentration of HEV RNA at baseline was 5.77 log copies/mL (range, 4.35-7.35 log copies/mL). Three months after ribavirin therapy commenced, HEV RNA was undetectable in serum samples from all patients. A sustained virologic response was observed in 4 patients; the other 2 patients relapsed at 1 and 2 months after ribavirin therapy ended. At the end of the study, all patients had normal levels of alanine and aspartate aminotransferase. Anemia was the main side effect caused by ribavirin therapy. CONCLUSIONS: Ribavirin monotherapy inhibits the replication of HEV in vivo and might induce a sustained virological response in patients with chronic HEV infections. Further studies are required to determine the optimal duration of ribavirin therapy. SN - 1528-0012 UR - https://www.unboundmedicine.com/medline/citation/20708006/Ribavirin_therapy_inhibits_viral_replication_on_patients_with_chronic_hepatitis_e_virus_infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(10)01169-8 DB - PRIME DP - Unbound Medicine ER -